Correlation of PI3KCAand extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC). Conference Paper uri icon

authors

  • Price, Timothy Jay
  • Bruhn, Maressa
  • Lee, Chee
  • Hardingham, Jenny
  • Townsend, Amanda Rose
  • Mann, Kristy
  • Simes, John
  • Weickhardt, Andrew James
  • Wrin, Joe
  • Wilson, Kate
  • Gebski, Val
  • Robinson, Bridget Anne
  • Van Hazel, Guy A
  • Cunningham, David
  • Tebbutt, Niall C

publication date

  • May 20, 2014